Overview

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label，phase II study designed to evaluate the efficacy and safety of Toripalimab plus nab-paclitaxel with or without cisplatin as first-line treatment of unresectable locally advanced or metastatic urothelial carcinoma.Each enrolled Patient will receive Toripalimab plus nab-paclitaxel with or without cisplatin until progressive disease or intolerable toxicity occurs, then enter a survival follow-up period. Nab-paclitaxel with or without cisplatin will be administered for up to 6 cycles, and Toripalimab up to 2 years.

Phase:

Phase 2

Details

Lead Sponsor:

Jun Guo

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel